Skip to main content

Advertisement

SpringerLink
Log in

The effect of cilostazol on electrophysiologic changes in non-proliferative diabetic retinopathy patients

  • Original Research Article
  • Published:
Documenta Ophthalmologica Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the effects of cilostazol, an antiplatelet and vasodilation agent, on the retinal function of patients with non-proliferative diabetic retinopathy (NPDR) using a full-field electroretinogram (ffERG).

Methods

A total of 20 eyes from 20 patients were enrolled as the cilostazol-treated group, and 16 eyes from 16 patients were enrolled as the control group to assess the functional effects of cilostazol. Ophthalmologic examinations including fundus fluorescein angiography (FFA), fundus color photography, optical coherence tomography (OCT), and ffERG responses were recorded at baseline and after 1 year of cilostazol treatment. The number of microaneurysms on FFA, the number of exudates on fundus photographs, and central macular thickness (CMT) on OCT were compared between the two groups. Recording of ffERG was also performed at baseline and repeated after 1 year of treatment. The mean implicit times and amplitudes of a- and b-waves in each ffERG response were analyzed to evaluate the retinal function.

Results

CMT and the numbers of microaneurysms and exudates showed no significant change in the cilostazol-treated group. There was no significant change in ffERG parameters between baseline and 1 year after the treatment in each group. The mean changes in implicit times from the cilostazol-treated group were significantly less than in the control group in b-waves from dark-adapted 3 ERG (p = 0.017) and 10 ERG responses (p = 0.047). On the other hand, the mean changes in amplitudes were not significant after 1 year of cilostazol treatment, but there were slight increases in amplitudes of dark-adapted 0.01 ERG and 10 ERG in the cilostazol-treated group.

Conclusions

These results suggest that cilostazol administration could reduce the implicit times of ffERG in patients with NPDR. It may be beneficial to preserve the retinal function in the diabetic retina, and additional research with larger populations and extended duration are needed to clarify the efficacy and safety of cilostazol for these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Aiello LP, Gardner TW, King GL et al (1998) Diabetic retinopathy. Diabetes Care 21:143–156

    Article  CAS  PubMed  Google Scholar 

  2. Malecki MT, Osmenda G, Walus-Miarka M et al (2008) Retinopathy in type 2 diabetes mellitus is associated with increased intima-media thickness and endothelial dysfunction. Eur J Clin Invest 38:925–930

    Article  CAS  PubMed  Google Scholar 

  3. Katakami N, Kim YS, Kawamori R et al (2010) The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation 121:2584–2591

    Article  CAS  PubMed  Google Scholar 

  4. Ahn CW, Lee HC, Park SW et al (2001) Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 52:45–53

    Article  CAS  PubMed  Google Scholar 

  5. Nishi T, Tabusa F, Tanaka T et al (1983) Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II. 6-[3-(1-cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline and related compounds. Chem Pharm Bull 31:1151–1157

    Article  CAS  PubMed  Google Scholar 

  6. Umekawa H, Tanaka T, Kimura Y et al (1984) Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography. Biochem Pharmacol 33:3339–3344

    Article  CAS  PubMed  Google Scholar 

  7. Tanaka T, Ishikawa T, Hagiwara M et al (1988) Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 36:313–320

    Article  CAS  PubMed  Google Scholar 

  8. Yamada N (1992) Clinical usefulness of cilostazol in patients with subjective symptoms caused by diabetes mellitus: multi-center Open Clinical Study. Jpn Pharmacol Ther 20:15–24

    Google Scholar 

  9. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820

    Article  CAS  PubMed  Google Scholar 

  10. Hammes HP, Lin J, Renner O et al (2002) Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51:3107–3112

    Article  CAS  PubMed  Google Scholar 

  11. Jung KI, Kim JH, Park HY et al (2013) Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats. J Pharmacol Exp Ther 345:457–463

    Article  CAS  PubMed  Google Scholar 

  12. Hotta H, Ito H, Kagitani F et al (1998) Cilostazol, a selective cAMP phosphodiesterase inhibitor, dilates retinal arterioles and increases retinal and choroidal blood flow in rats. Eur J Pharmacol 344:49–52

    Article  CAS  PubMed  Google Scholar 

  13. Early Treatment Diabetic Retinopathy Study Research Group (1991) Grading diabetic retinopathy from stereoscopic color fundus photographs–an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 98:786–806

    Article  Google Scholar 

  14. Novo S (2002) Classification, epidemiology, risk factors, and natural history of peripheral arterial disease. Diabetes Obes Metab 4(Suppl 2):S1–S6

    Article  PubMed  Google Scholar 

  15. McCulloch DL, Marmor MF, Brigell MG et al (2015) ISCEV standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol 130:1–12

    Article  PubMed  Google Scholar 

  16. Tzekov R, Arden GB (1999) The electroretinogram in diabetic retinopathy. Surv Ophthalmol 44:53–60

    Article  CAS  PubMed  Google Scholar 

  17. Matsubara H, Kuze M, Sasoh M et al (2006) Time-dependent course of electroretinograms in the spontaneous diabetic Goto-Kakizaki rat. Jpn J Ophthalmol 50:211–216

    Article  PubMed  Google Scholar 

  18. Luu CD, Szental JA, Lee SY et al (2010) Correlation between retinal oscillatory potentials and retinal vascular caliber in type 2 diabetes. Invest Ophthalmol Vis Sci 51:482–486

    Article  PubMed  Google Scholar 

  19. Park SE, Sun HJ, Lee HJ et al (2010) The role of electroretinography in assessing the progression of diabetic retinopathy. J Korean Ophthalmol Soc 51:693–699

    Article  Google Scholar 

  20. Bresnick GH, Palta M (1987) Oscillatory potential amplitudes. Relation to severity of diabetic retinopathy. Arch Ophthalmol 105:929–933

    Article  CAS  PubMed  Google Scholar 

  21. Parker JC, VanVolkenburg MA, Ketchum RJ et al (1995) Cyclic AMP phosphodiesterases of human and rat islets of Langerhans: contributions of types III and IV to the modulation of insulin secretion. Biochem Biophys Res Commun 217:916–923

    Article  CAS  PubMed  Google Scholar 

  22. Takazakura E, Ohsawa K, Hamamatsu K (1989) Effect of cilostazol (Pletaal) on serum lipid levels in diabetic patients. Jpn Pharmacol Ther 17:341–345

    Google Scholar 

  23. Kashimoto R, Kurimoto T, Miyoshi T et al (2008) Cilostazol promotes survival of axotomized retinal ganglion cells in adult rats. Neurosci Lett 436:116–119

    Article  CAS  PubMed  Google Scholar 

  24. Kwak MS, Kim SH (1994) The electroretinogram a- and b-wave in diabetic retinopathy. J Korean Ophthalmol Soc 35:1081–1087

    Google Scholar 

  25. Yonemura D, Aoki T, Tsuzuki K (1962) Electroretinogram in diabetic retinopathy. Arch Ophthalmol 68:19–24

    Article  CAS  PubMed  Google Scholar 

  26. Holopigian K, Seiple W, Lorenzo M et al (1992) A comparison of photopic and scotopic electroretinographic changes in early diabetic retinopathy. Invest Ophthalmol Vis Sci 33:2773–2780

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Soonchunhyang University Research Fund. The sponsor had no role in the design or conduct of this research.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, College of Medicine, Soonchunhyang University, Cheonan, Republic of Korea

    Hoon Dong Kim

  2. Department of Ophthalmology, Eulji University, Daejeon, Republic of Korea

    Si Hyoung Lee

  3. Department of Ophthalmology, College of Medicine, Soonchunhyang University, Bucheon, Republic of Korea

    Yoon Kyoung Kim, Jong Rok Oh & Young-Hoon Ohn

Authors
  1. Hoon Dong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Si Hyoung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoon Kyoung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jong Rok Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Young-Hoon Ohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Young-Hoon Ohn.

Ethics declarations

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, H.D., Lee, S.H., Kim, Y.K. et al. The effect of cilostazol on electrophysiologic changes in non-proliferative diabetic retinopathy patients. Doc Ophthalmol 133, 49–60 (2016). https://doi.org/10.1007/s10633-016-9550-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10633-016-9550-1

Keywords

Search

Navigation